Skip to main content

Latest news


Catch up with the research news, approvals, and guideline updates in rheumatology.


20-12-2022 | Osteoarthritis | News

Support for further investigation of metformin in people with osteoarthritis

Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.

Antibodies, immunoglobulin Ig proteins 3D medical background

19-12-2022 | Systemic lupus erythematosus | News

Anti-dsDNA antibodies have potential to guide targeted therapy use in SLE

An exploratory analysis of data from the phase 2b BEAT LUPUS trial suggests that IgA2 anti-dsDNA antibody levels may be able to predict response to B cell-targeted therapies in patients with systemic lupus erythematosus.

15-12-2022 | JAK inhibitors | News

EMA restricts JAK inhibitor use in high-risk patient groups

Click through for further details on this safety announcement

13-12-2022 | Baricitinib | News

Baricitinib linked to increased risk for VTE

Real-world study findings suggest that people with rheumatoid arthritis treated with the JAK inhibitor baricitinib may have a higher risk for venous thromboembolism than those on TNF inhibitors.

Doctor holding virtual heart in hand. - healthcare concept

07-12-2022 | Rheumatoid arthritis | News

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

06-12-2022 | Gout | News

CA72-4 independently associated with gout flare risk in people initiating ULT

Results from a prospective cohort study suggest that increased levels of serum CA72-4 at urate-lowering therapy initiation are an independent risk factor for recurrent gout flares.

02-12-2022 | Systemic sclerosis | News

Anti-SSSCA1 positivity tied to cancer risk in SSc patients

Study findings reported in Rheumatology suggest that anti-SSSCA1 antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis.

29-11-2022 | Gout | News

The metabolic syndrome may influence the risk for gout

The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.

Simple 3d scene representing arrows, that hit targets with blackvision - target concept

28-11-2022 | Rheumatoid arthritis | News

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

23-11-2022 | ACR 2022 | Conference coverage | News

LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren's syndrome in a phase 2 study.

21-11-2022 | ACR 2022 | Conference coverage | News

Abortion restrictions impede methotrexate access for some rheumatology patients

Patients with rheumatic diseases have reported issues with access to methotrexate following changes to abortion laws, show findings from a questionnaire study conducted in the USA.

Debate (concept)

18-11-2022 | ACR 2022 | Conference coverage | News

A Great Debate: To treat or not to treat in pre-RA?

In one of two Great Debate sessions at ACR Convergence 2022 in Philadelphia, Pennsylvania, USA, two experts teamed up to provide opposing stands on whether now is the right time to be treating people at risk for rheumatoid arthritis in the preclinical stages of the condition in order to prevent disease onset.

17-11-2022 | ACR 2022 | Conference coverage | News

Secukinumab comparable to adalimumab biosimilar in axSpA

Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

17-11-2022 | ACR 2022 | Conference coverage | News

New score could predict ILD development in people with SSc

Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.

16-11-2022 | ACR 2022 | Conference coverage | News

JUVE-BASIS: Support for baricitinib in juvenile arthritis

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

16-11-2022 | ACR 2022 | Conference coverage | News

PD-1 receptor agonist may represent a novel treatment for patients with RA

Peresolimab, a PD-1 receptor agonist, may represent a promising approach to treating rheumatoid arthritis, with an “encouraging” safety profile, suggests research reported at the ACR Convergence 2022 in Philadelphia, Pennsylvania, USA.

15-11-2022 | ACR 2022 | Conference coverage | News

Community-based diet, exercise program could benefit people with knee osteoarthritis

A diet and exercise program delivered in community settings may improve some clinical outcomes for people with knee osteoarthritis and overweight or obesity, suggest findings from the WE-CAN pragmatic randomized controlled trial.

3D illustration of Lungs

15-11-2022 | ACR 2022 | Conference coverage | News

RECITAL: Rituximab represents alternative to cyclophosphamide for CTD-ILD

Rituximab and cyclophosphamide have similar overall efficacy in patients with connective tissue disease-associated interstitial lung disease, but rituximab may be associated with fewer adverse events, suggest findings from a phase 2b trial.

15-11-2022 | ACR 2022 | Conference coverage | News

COVID-19 vaccination advocated for pregnant women with RMDs

COVID-19 vaccination should be actively promoted for women with rheumatic and musculoskeletal diseases who are pregnant or planning a pregnancy, say researchers.

Close up of medical disposable syringe and vial

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.


The Medicine Matters news service is brought to you in partnership with medwireNews